Skip to main content
Terug
Watch Compare

HCW Biologics Inc.

Datakwaliteit: 83%
HCWB
NASDAQ Manufacturing Chemicals
€ 0,35
▼ € 0,01 (-3,37%)
Marktkapitalisatie: 2,27 M
Prijs
€ 0,34
Marktkapitalisatie
2,27 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -13,39 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-149,86%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,06
Interest Coverage-15,58

Waardering

PE (TTM)
-0,29
Boven sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3

Koersdoel Analisten

1 analist
Strong Buy
Huidig
€ 0,35
+467.9%
Koersdoel
€ 2,00
€ 2,00
€ 2,00
€ 2,00
Vooruitzicht
Forward WPA -€ 0,55
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,55
-€ 0,55 – -€ 0,55
 0,0 1
FY2026 -€ 0,96
-€ 0,96 – -€ 0,96
 0,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,84 -€ 1,02 -21,4%
Q32025 € 1,58 -€ 2,02 -227,9%
Q22025 € 1,80 -€ 6,79 -477,2%
Q12025 N/A -€ 0,05 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7,96 M
ROE N/A ROA -29,29%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -13,39 M
ROIC -149,86% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,06
Interest Coverage -15,58 Asset Turnover N/A
Working Capital -25,27 M Tangible Book Value -2,11 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,29 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -589,57%
Market Cap 2,27 M Enterprise Value 7,98 M
Per Share
EPS (Diluted TTM) -10,63 Revenue / Share N/A
FCF / Share -1,99 OCF / Share -1,99
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 168,24%
SBC-Adj. FCF -14,38 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Revenue — — — 4,10 M —
Net Income -7,96 M -30,02 M -24,99 M -12,86 M -14,90 M
EPS (Diluted) -10,63 -0,77 -0,70 — -0,42
Gross Profit 10.846,0 959.403,0 560.360,0 — 2,59 M
Operating Income -13,16 M -29,48 M -25,72 M -13,37 M -15,08 M
EBITDA — — — — —
R&D Expenses 5,44 M 6,39 M 7,68 M 8,17 M 9,34 M
SG&A Expenses — — — — —
D&A — 1,18 M 1,14 M 543.598,0 717.854,0
Interest Expense 845.051,0 631.137,0 283.042,0 — 126.660,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Total Assets 24,52 M 30,24 M 28,51 M 53,51 M 46,81 M
Total Liabilities 21,76 M 37,01 M 15,05 M — 9,38 M
Shareholders' Equity 2,76 M -6,77 M 13,46 M 51,19 M 37,43 M
Total Debt 6,81 M 13,69 M 6,30 M — 6,41 M
Cash & Equivalents 1,95 M 4,67 M 3,60 M 11,73 M 22,33 M
Current Assets 2,28 M 5,70 M 6,40 M 40,48 M 34,07 M
Current Liabilities 21,06 M 29,63 M 8,75 M 2,32 M 2,96 M